Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
stocks
Cheap Narrow Moat ASX share continues to face negative sentiment
Earnings growth fails to excite investors worried about AI disruption.
stocks
ASX energy giant remains cheap following record production
Impressive cost control and record production leads to higher dividend.
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,359.00 | 50.70 | 0.54% |
| CAC 40 | 8,519.21 | 22.04 | 0.26% |
| DAX 40 | 24,986.25 | 5.72 | -0.02% |
| Dow JONES (US) | 49,174.50 | 370.44 | 0.76% |
| FTSE 100 | 10,680.59 | 4.15 | -0.04% |
| HKSE | 26,733.55 | 143.23 | 0.54% |
| NASDAQ | 22,863.68 | 236.41 | 1.04% |
| Nikkei 225 | 58,583.12 | 1,262.03 | 2.20% |
| NZX 50 Index | 13,525.58 | 6.73 | -0.05% |
| S&P 500 | 6,890.07 | 52.32 | 0.77% |
| S&P/ASX 200 | 9,128.30 | 44.20 | 0.49% |
| SSE Composite Index | 4,140.40 | 22.99 | 0.56% |